ALZEX BIOMEDICAL

Technology for the Treatment of Alzheimer’s

FORWARD LOOKING STATEMENTS

This presentation is not intended as a solicitation or offering of securities in any jurisdiction and the information contained herein in no way should be construed or interpreted as such. No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by Alzex Bio Medical Group (the "Company") to that effect.

Cautionary Note Regarding Forward-Looking Statements

This presentation includes and is based in part upon forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and US securities legislation. All statements included herein, other than statements of historical fact, including, without limitation, plans for and intentions with respect to the company's capitalization, preparation of technical reports,, budgets, projected expenditures and other milestones, are forward- looking statements. Although Alzex Bio Medical Group. (the "Company") believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically, but not always, identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ .The Company undertakes no obligation to reissue or update any forward-looking statements as a result of new information or events after the date hereof except as may be required by law. All forward- looking statements and information herein are qualified by this cautionary statement.

ALZEX BIOMEDICAL

TABLE OF CONTENTS

ALZEX BIOMEDICAL

ABOUT ALZEX BIO MEDICAL (VFP THERAPIES INC.)

Alzex Bio Medical Group is a private company that has acquired VFP Therapies Inc. out of France. VFP Therapies is a collaboration of researchers, scientists, and investors that have developed and patented precision therapeutics for the treatment of Alzheimer's and other neurological diseases.

VFP Therapies currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineer and research institute.

Our North American headquarters are located in Vancouver B.C with our VFP Therapies laboratories located in France.

ALZEX BIOMEDICAL

SCIENTIFIC MISSION

- The BIOPRECURSORS, VFP Therapies have developed will be considered as drugs *de novo* and not as new delivery systems.
- As the bioactive forms are mimicking commercially well known drugs (Aricept / Esai-Pfizer and Exelon / Novartis) with similar biological targets, we will take advantage of known animal models for the first phases and clinical development programs for the clinical phases.
- Our ambition is to push at least one drug candidate into Phase 1 within 6 months and to complete Phase 1 within 12-18 months.
- Such a record, if positive, will allow VFP to enter into discussions with pharmaceutical companies either to license our families of products or to negotiate a co-development program for their own Alzheimer drugs or other treatments for central nervous system diseases.
- With the benefit of over ten years of research by VFP Scientists, the VFP approach brings an innovative response to minimizing the noxious side-effects of drugs as well as overcoming crossing the Blood-Brain-Barrier issue. The completed R & D studies have already demonstrated the technical proof of its concept in initial in vitro and in vivo models.

ALZEX BIOMEDICAL

ALZHEIMER'S: LOSS OF THE HUMAN MIND

- The gradual deterioration of a lifetime's worth of wisdom, experience and personal relationships
- There was a time when cognitive impairment was considered a natural part of growing old. That is no longer the case.
- Fight about whether beta amyloid plaques or tau tangles were the cause of Alzheimer's, it looks like both.
- The accumulation of these protein derived plaques and tangles leads to the death of nerve cells, eventually causing dementia .
- Researchers are debating whether Alzeheimer's results from the overproduction of the protein in the brain or from the brain's in ability to clear away the amyloid properly.

SEARCHING FOR THE CURE

The search for a drug to treat Alzheimer's disease, the most common form of dementia, has been marked by clinical trial failures.

A new report from top researchers says the number of drugs advancing through clinical phase two and phase three trials provides reason to believe that breakthroughs may be in the current pharmaceutical pipeline.

The dementia scientists are worried that the history of failures has left the health-care system unprepared to diagnose and treat patients if a breakthrough Alzheimer's drug becomes available.

Fifty million people worldwide and six million Americans are living with Alzheimer’s, and the number is expected to rise sharply.

ALZEX BIOMEDICAL

THE BIOPRECURSOR

- Our Bioprecursor molecule may present a new, safe way to mimic the current Alzheimer's drugs, such as Aricept or Exilon.

- Same biological target (an enzyme called acetylcholine esterase).

- Similar and original chemical structures under a specially modified chemical structure which allows the Bioprecursor to avoid (or to lower) undesired side-effects.

- The Bioprecursor is an inactive form which is not (or little) recognized by the biological receptors outside the brain. VFP's Bioprecursor is able to cross the Blood Brain Barrier (**BBB**) before transforming into the active form which then induces the desired biological effects.

- Our Bioprecursor should be able to deliver symptomatic relief for a far longer period and at a far higher dosage, due to our potential ability to alleviate symptoms without the serious and debilitating side effects of current drugs extent.

ALZEX BIOMEDICAL

BRAIN TARGETING BIOPRECURSOR

VFP Therapies Innovative Concept of Bioprecursor

- No recognition by the biological receptors
- Lipophilic molecule crossing the BBB

Bioprecursor Activated inside the Brain

- Recognition by the biological receptors
- Induction of the targeted pharmacological effects
- Limitation of peripheral side-effects

Proof of Concept is Achieved

- Successful design of new analog drugs for AD
- Bioprecursor technology can be applied to other brain diseases

ALZEX BIOMEDICAL

DUAL TECHNOLOGY PLATFORM

VFP Therapies Carrier Technology

- No biological activity outside the brain
- Selective activity inside the brain
- Specific carriers fitted to drug and brain target
- Drug bioavailability enhancement
- Selective release inside the brain

Both Technologies can be applied to most Drugs for Brain Diseases

ALZEX BIOMEDICAL

WORLDWIDE PATENTS

PATENT 1

Patent **WO2006/102130** has been filed in 2006 by the INSA of Rouen (my academic establishment) and it has been totally repurchased in 2014 by VFP. It covers a large family of drug candidates which could be marketed in future to compete commercial drugs like Exelon® (rivastigmine). The patent has been granted in the main worldwide countries and the annuities have been regularly paid (Australia, Canada, Europa, Israel, New-Zealand, Republic of South-Africa, Singapore and United States of America).

Due to unexpected genotoxic effects of some leads, a second family of drug candidates has been developed bearing the same chemical core but with an optimized key substituent. This new family is currently being exemplified, 2-3 leads have been identified and a selection patent should be filed in 2018.

PATENT 2

Patent **WO2014/114742** has been filed (PCT) by VFP 70% and its academic partners 30% (CNRS, INSA of Rouen and University of Rouen). It covers a large family of drug candidates which could be marketed in future to compete commercial drugs like Aricept® (donepezil).

The PCT procedure has been launched in January 2015, the patent has been granted in United States of America and in Europe, it is currently under examination in the selected filing countries (Australia, Canada and Israel).

ALZEX BIOMEDICAL

R & D RESULTS

1. DONE: Selection of some hits/active molecules on the targeted biological receptor by using in vitro trials.

2. DONE: Proof of concept which implies proof that such hits are active on animals by any administrative way (Irwing test).

3. DONE: Selection of some lead molecules through supplementary trials:
   - Physicochemical optimisation: solubility, stability...
   - Biological screening in order to avoid undesirable biological effects: genotoxicity, enzymatic screening

   This risk of failure has been anticipated by preparing backup molecules during point 3.

4. UNDERWAY: Preclinical Assays: the selected leads molecules (possible drug candidates) will be subjected to preclinical studies, which take place just before clinical trials (the testing phase in humans). The main goals of pre-clinical studies are to determine the safe dose for first-in-human studies and assess the product's safety profile.

CHEMICAL OPTIMIZATION ACHIEVED: 3 LEADS IDENTIFIED

- Invitro selection and physico chemical optimization
- Successful Enzymatic screening (by blocking the digestive/degradation of the neurotransmitter Aceylcholine one increases the Aceytylcholine)

ALZEX BIOMEDICAL

SCIENTIFIC RESEARCH PARTNERS

INSA ROUEN NORMANDIE

ICM Institut du Cerveau et de la Moelle épinière

cnrs dépasser les frontières

UNIVERSITÉ DE ROUEN

ALZEX BIOMEDICAL

TECHNOLOGICAL PARTNERS



eurofins

Credible Results. Incredible Service.™

CiToxLAB

GLOBAL EXPERTISE, LOCAL RESPONSE

ALZEX BIOMEDICAL

FINANCIAL SUPPORT PARTNERS

ALZEX BIOMEDICAL

CURRENT OFFERING

Our current funding requirements to enter into Phase 1 of clinical human trials within the next 6 months will be $1.2 million CAD.

FINANCING TERMS

PRICE: CDN$0.25 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase, for a period of 12 months from the date of issue (the "**Expiry Time**"), one additional common share of the Issuer at an exercise price of Cdn$0.30 per share.

AMOUNT: $2 million

USE OF PROCEEDS: Phase 1 of clinical human trials - commencing within 6 months of September 2018 and general working capital.

ALZEX BIOMEDICAL

CAPITAL STRUCTURE

Current Shares Out

18,000,000 shares in private co. (Alzex Bio Medical Group Inc.)

Post Financing Shares

8,000,000 Shares @ $0.25

8,000,000 Warrants @ $0.30

Issued & Outstanding: 26,000,000

Fully Diluted: 32,000,000

ALZEX BIOMEDICAL

SCIENTIFIC RESEARCH TEAM

Dr. Francis Marsais

Francis Marsais, Ph.D. in Organic Chemistry, was the Managing Director of the Institut de Recherche en Chimie Organique Fine (IRCOF) from 1997 to 2010. He was also the director in charge of partnerships at INSA, Institut National des Sciences Appliquées, a major French academic engineer and research institute, from 2007 to 2011. Dr. Marsais has published over 120 official articles and holds 3 patents.

Dr. Vincent Gembus

Vincent Gembus received his PhD in Organic Chemistry from the Louis Pasteur University in Strasbourg (France). From 2007 to early 2012 he worked in three different postdoctoral positions at the CNRS Rouen in the COBRA team. Dr. Gembus has published numerous papers and holds 2 patents.

ALZEX BIOMEDICAL

ADVISORY BOARD

Dr. Fabrice Heitzmann:
Ph.D. in Life Sciences

Dr. Patrice Binay:
Ph.D. in Organic Chemistry

Dr. Vincent Levacher:
Ph.D. in Organic Chemistry

Dr. Thierry Besson:
DEA of Biophysico Chemistry, Cellular and Molecular Biology

Dr. Pascal George:
Ph.D. in Organic Chemistry

Bojan Krasic:
President, Beleave Kannabis Corp.

ALZEX BIOMEDICAL

CONTACT INFO

Canadian Head Office

Alzex Bio Medical Group Inc.
666 Burrard St, 5th Floor
Vancouver , BC, Canada
V6C 2X8

info@Alzex.ca

France Head Office

15, rue François Couperin
76000 Rouen
France

info@Alzex.ca

Research Lab 325 IRCOF

rue Lucien Tesnière
76130 Mont-Saint-Aignan
France

ALZEX BIOMEDICAL